Check Out What Whales Are Doing With IOVA

A whale with a lot of money to spend has taken a noticeably bullish stance on Iovance Biotherapeutics.

Looking at options history for Iovance Biotherapeutics IOVA we detected 10 strange trades.

If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.

From the overall spotted trades, 4 are puts, for a total amount of $551,400 and 6, calls, for a total amount of $666,718.

Get Started

Start Futures Trading Fast — with a $200 Bonus

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.

Get Started

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $10.0 for Iovance Biotherapeutics over the last 3 months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Iovance Biotherapeutics's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Iovance Biotherapeutics's whale activity within a strike price range from $5.0 to $10.0 in the last 30 days.

Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Where Is Iovance Biotherapeutics Standing Right Now?

• With a volume of 16,055,956, the price of IOVA is down -11.68% at $4.8.
• RSI indicators hint that the underlying stock may be oversold.
• Next earnings are expected to be released in 49 days.

What The Experts Say On Iovance Biotherapeutics:

• JMP Securities downgraded its action to Market Outperform with a price target of $18
• Chardan Capital downgraded its action to Buy with a price target of $29
• Stifel has decided to maintain their Buy rating on Iovance Biotherapeutics, which currently sits at a price target of $25.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Iovance Biotherapeutics, Benzinga Pro gives you real-time options trades alerts.